The characteristics of determination of BRCA1 and BRCA2 mutations in serous ovarian cancer
Mutations of the BRCA1/BRCA2 genes occur in 15-20% cases of ovarian cancer (OC) and are associated with increased sensitivity to platinum drugs and new target drugs that inhibit proteins of poly(ADP-ribose) polymerase family. The discovery of new therapeutic options in the treatment of patients with...
Main Author: | I A Demidova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2017-01-01
|
Series: | Современная онкология |
Subjects: | |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/27116/pdf |
Similar Items
-
Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
by: Chuanlin Wang, et al.
Published: (2022-12-01) -
BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients
by: Yinmei Zhang, et al.
Published: (2024-01-01) -
BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
by: Salar Farokhi Boroujeni, et al.
Published: (2023-11-01) -
Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01) -
Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
by: Andrzej Jasiewicz, et al.
Published: (2022-04-01)